---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012381"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T21:57:44.825579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target

## Summary
- Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.
- Fate receives research funding through Sep 2024 and is eligible for an option exercise fee, milestones, and tiered royalties.
- Fate retains global manufacturing rights and the right to co-develop and co-commercialize in the US and Europe.
- First iPSC-derived CAR T-cell product candidate targeting solid tumors is advancing toward clinical development.

## SEC filing metadata
- accession: 0000950170-22-012381
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/0000950170-22-012381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/fate-20220628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012381
- JSON: https://secwatch.observer/filing/0000950170-22-012381.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.